Excessive growth of the gingiva either by an increase in the size of the constituent cells (GINGIVAL HYPERTROPHY) or by an increase in their number (GINGIVAL HYPERPLASIA). (From Jablonski's Dictionary of Dentistry, 1992, p574)
Non-inflammatory enlargement of the gingivae produced by factors other than local irritation. It is characteristically due to an increase in the number of cells. (From Jablonski's Dictionary of Dentistry, 1992, p400)
Oral tissue surrounding and attached to TEETH.
Generalized or localized diffuse fibrous overgrowth of the gingival tissue, usually transmitted as an autosomal dominant trait, but some cases are idiopathic and others produced by drugs. The enlarged gingiva is pink, firm, and has a leather-like consistency with a minutely pebbled surface and in severe cases the teeth are almost completely covered and the enlargement projects into the oral vestibule. (Dorland, 28th ed)
'Gingival diseases' is a general term for conditions affecting the soft tissues surrounding and supporting the teeth, primarily characterized by inflammation, bleeding, redness, or swelling, which can progress to periodontal disease if left untreated.
Surgical excision of the gingiva at the level of its attachment, thus creating new marginal gingiva. This procedure is used to eliminate gingival or periodontal pockets or to provide an approach for extensive surgical interventions, and to gain access necessary to remove calculus within the pocket. (Dorland, 28th ed)
An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs.
An abnormal extension of a gingival sulcus not accompanied by the apical migration of the epithelial attachment.
Inflammation of gum tissue (GINGIVA) without loss of connective tissue.
An index which scores the degree of dental plaque accumulation.
A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).
A disorder of the skin, the oral mucosa, and the gingiva, that usually presents as a solitary polypoid capillary hemangioma often resulting from trauma. It is manifested as an inflammatory response with similar characteristics to those of a granuloma.
A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.
A numerical rating scale for classifying the periodontal status of a person or population with a single figure which takes into consideration prevalence as well as severity of the condition. It is based upon probe measurement of periodontal pockets and on gingival tissue status.
Devices used for influencing tooth position. Orthodontic appliances may be classified as fixed or removable, active or retaining, and intraoral or extraoral. (Boucher's Clinical Dental Terminology, 4th ed, p19)
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
A broad specificity HLA-DR antigen that is associated with HLA-DRB1 CHAINS encoded by DRB1*01:15 and DRB1*01:16 alleles.
Dental care for patients with chronic diseases. These diseases include chronic cardiovascular, endocrinologic, hematologic, immunologic, neoplastic, and renal diseases. The concept does not include dental care for the mentally or physically disabled which is DENTAL CARE FOR DISABLED.
A fluid occurring in minute amounts in the gingival crevice, believed by some authorities to be an inflammatory exudate and by others to cleanse material from the crevice, containing sticky plasma proteins which improve adhesions of the epithelial attachment, have antimicrobial properties, and exert antibody activity. (From Jablonski, Illustrated Dictionary of Dentistry, 1982)
A class of drugs that act by selective inhibition of calcium influx through cellular membranes.
A CCN protein family member that regulates a variety of extracellular functions including CELL ADHESION; CELL MIGRATION; and EXTRACELLULAR MATRIX synthesis. It is found in hypertrophic CHONDROCYTES where it may play a role in CHONDROGENESIS and endochondral ossification.
Drugs used to prevent SEIZURES or reduce their severity.
'Gingival neoplasms' are abnormal, uncontrolled growths of tissue originating from the gingiva, which can be benign (non-cancerous) or malignant (cancerous), often manifesting as swellings, ulcerations, or masses within the oral cavity.
Tissue that supports and binds other tissues. It consists of CONNECTIVE TISSUE CELLS embedded in a large amount of EXTRACELLULAR MATRIX.
The transference of a kidney from one human or animal to another.

Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth: a study with cathepsin-L-deficient mice. (1/47)

Drug-induced gingival overgrowth, the chronic side effect of calcium antagonists, is frequently seen due to the increase in patients with hypertension, although the etiology of the disease is largely unknown. I-cell disease, which accompanies gingival overgrowth, is characterized by a deficiency in UDP-N-acetyl-glucosamine and is classified as one of the lysosomal storage diseases. Here, we hypothesized that a common mechanism may underlie the etiology of gingival overgrowth seen in patients treated with calcium antagonist and in patients with I-cell disease. A calcium antagonist, nifedipine, specifically suppressed cathepsin-L activity and mRNA expression, but not that of cathepsin-B in cultured gingival fibroblasts. The activity of cathepsin-L was suppressed up to 50% at 24 hours after treatment of the cells with the reagent. The selective suppression of cathepsin-L activity appeared not to be dependent on Ca(2+), since treatment of the cells with thapsigargin suppressed both cathepsin-B and -L activity. Mice deficient in the cathepsin-L gene manifested enlarged gingivae. Histological observation of the gingivae demonstrated typical features of acanthosis, a phenotype very similar to that of experimentally induced gingival overgrowth. Since cathepsin-L deficiency was reported to be associated with thickening of the skin, impaired cathepsin-L activity may play a key role in the establishment of skin and gingival abnormalities seen in I-cell disease. In addition, reduced cathepsin-L activity may play an important role in inducing drug-induced gingival overgrowth.  (+info)

The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. (2/47)

PURPOSE: This investigation was performed to evaluate the effect of cyclosporine alone and in combination with nifedipine on gingival overgrowth. METHODS: One hundred and nineteen patients who had undergone renal transplantation at least 12 months previously were selected for the study. The patients were divided into 2 groups according to whether they had received cyclosporine alone (group 1, n = 98) or cyclosporine with nifedipine (group 2, n = 21). Periodontal and pharmacological characteristics were assessed for all patients. RESULTS: Marked gingival overgrowth was seen in 11 (52%) of the patients in group 2 but just 6 (6%) of those in group 1. In addition, the gingival overgrowth index was significantly greater for patients who had received both nifedipine and cyclosporine (Mann-Whitney U-test, p < 0.001). However, there were no significant differences between groups with higher and lower gingival overgrowth index in terms of age, sex, cyclosporine dose, nifedipine dose or level of cyclosporine in the serum. CONCLUSION: The combination of cyclosporine and nifedipine may increase the incidence as well as the severity of gingival overgrowth in renal transplant patients. Among patients who had received both drugs, there was a clear relationship between gingival overgrowth and duration of cyclosporine and nifedipine use.  (+info)

Phenytoin-induced gingival overgrowth in un-cooperated epilepsy patients. (3/47)

Phenytoin-induced gingival overgrowth is a well-known and frequently reported gingival lesion, which was first detected in 1939. However, there are conflicts in the literature about the agents which affect the severity of the lesion. Un-cooperative dental patients are one of the most unsuccessfully treated periodontal patient groups because of the difficulty in maintaining their oral hygiene. This case report consists of two cases with the same characteristics: phenytoin usage, comprehension and speech defects and poor oral hygiene, but each case differs in the duration of the phenytoin therapy. Both of the cases received scaling, root planning and a gingivectomy.  (+info)

High prevalence of Chlamydia pneumoniae infection in cyclosporin A-induced post-transplant gingival overgrowth tissue and evidence for the possibility of persistent infection despite short-term treatment with azithromycin. (4/47)

BACKGROUND: Cyclosporin A (CsA) induces gingival overgrowth (GO) in up to a quarter of CsA-treated renal transplant recipients. A short-term therapy with azithromycin effectively reduces GO, indicating a possible involvement of microorganisms in the pathogenesis of CsA-induced GO. We aimed to determine if there could be any relationship between infection with Chlamydia pneumoniae and GO pathogenesis. In addition, we determined the long-term persistence rate of C. pneumoniae infection in residual GO tissue when azithromycin treatment failed to eliminate GO. METHODS: Chlamydia pneumoniae IgG and IgM antibody titres were measured by microimmunofluorescence technique in sera of kidney recipients with (n = 11) and without (n = 89) GO. GOs were rated and gingivectomies were performed before treatment with 500 mg of azithromycin for 3 days and at months 6 and 12 post-treatment when C. pneumoniae titres were re-evaluated. Nested polymerase chain reaction was performed to identify C. pneumoniae-specific DNA in GO tissues. Results of C. pneumoniae antibody titres from patients with GO were compared with pair-matched controls without GO. RESULTS: Chlamydia pneumoniae IgM titres were elevated in five of 11 patients with GO and in none without GO, whereas the difference of C. pneumoniae IgG titres between patients with GO and pair-matched controls did not reach significance (P<0.57). Chlamydia pneumoniae-specific DNA was found in 10 of 11 GO tissue samples pre-treatment. Azithromycin therapy effectively reduced GO and C. pneumoniae IgM titres. In residual GO, C. pneumoniae-specific DNA remained detectable after 1 year in all GO tissue samples despite azithromycin treatment. The C.pneumoniae IgM titres correlated with GO scores. CONCLUSION: Chlamydia pneumoniae infection is highly prevalent in CsA-induced GO. The infection can persist over a long period in residual GO despite short-term azithromycin therapy. The results indicate that CsA immunosuppression enhances C. pneumoniae infection rates in non-cardiovascular tissue.  (+info)

The effect of basic fibroblast growth factor on cell cycle in human gingival fibroblasts from nifedipine responder and non-responder. (5/47)

It has previously been demonstrated that gingival fibroblasts derived from nifedipine-reactive patients (nifedipine responders) show a greater cell proliferation rate than those from nifedipine non-reactive patients (nifedipine non-responders) in the presence of 1 microM nifedipine. The aim of the present study was to characterize cell cycle differences between nifedipine responder and non-responder fibroblast cells and determine the effect of basic fibroblast growth factor (bFGF) on cell cycle progression. Further, the effect of bFGF on cyclins A, B1, D1, E, and CDKs 1, 2, 4, 6 mRNA expression in responder and non-responder cells was investigated. A population of nifedipine responder cells underwent progression to S and G2/M phases from G0/G1 phase in the presence of 10% fetal calf serum or 10 ng/ml bFGF was greater than nifedipine non-responder cells. mRNA expression of cyclins A, B1, D1, E and CDKs 1, 2, 4, 6 in the presence of 10 ng/ml bFGF was generally greater in nifedipine responder cells than non-responder cells. These results indicate that nifedipine responder cells may be more susceptible to growth factors such as bFGF with a resultant increase in expression of cyclins and CDKs in responder compared with non-responder cells.  (+info)

Risk factors of gingival overgrowth in kidney transplant recipients treated with cyclosporine A. (6/47)

OBJECTIVES: Gingival overgrowth is a common side effect of cyclosporine A (CsA) therapy. The pathogenesis of CsA-induced gingival overgrowth is still debated. The influence of CsA dosage and its trough level, HLA phenotype, gender and the administered calcium channel blocker on incidence and severity of overgrowth were studied. Moreover, relationship of overgrowth with plasma level of TGF-beta I was assessed. METHODS: Degree and extent of gingival overgrowth were tested in 124 kidney transplant recipients treated with CsA, in 9 patients treated with azathioprine and in 21 patients treated with tacrolimus, and various calcium channel blockers. RESULTS: Gingival overgrowth was found in 46% of patients treated with CsA. Total yearly CsA dosage was significantly higher in patients with overgrowth. Gingival overgrowth was observed in: 86% of patients treated with nifedipin, 47% with amlodipine, 35% with verapamil. HLA-DR antigens analysis showed that half of the patients with DR-2 allele suffered from overgrowth. Gingival overgrowth was found twice as often in males than in females. Plasma level of TGF-beta I was similar in patients with or without overgrowth. Gingival overgrowth was not found in patients treated with azathioprine or tacrolimus despite that half of the patients received nifedipine or amlodipine. CONCLUSIONS: The study revealed high frequency of overgrowth in renal graft recipients treated with CsA. Overgrowth severity was larger in patients treated simultaneously with nifedipine or amlodipine. CsA dosage, male sex and HLA-DR2 phenotype were risk factors of gingival overgrowth. None of the patients treated with tacrolimus suffered from gingival overgrowth.  (+info)

Connective tissue metabolism and gingival overgrowth. (7/47)

Gingival overgrowth occurs mainly as a result of certain anti-seizure, immunosuppressive, or antihypertensive drug therapies. Excess gingival tissues impede oral function and are disfiguring. Effective oral hygiene is compromised in the presence of gingival overgrowth, and it is now recognized that this may have negative implications for the systemic health of affected patients. Recent studies indicate that cytokine balances are abnormal in drug-induced forms of gingival overgrowth. Data supporting molecular and cellular characteristics that distinguish different forms of gingival overgrowth are summarized, and aspects of gingival fibroblast extracellular matrix metabolism that are unique to gingival tissues and cells are reviewed. Abnormal cytokine balances derived principally from lymphocytes and macrophages, and unique aspects of gingival extracellular matrix metabolism, are elements of a working model presented to facilitate our gaining a better understanding of mechanisms and of the tissue specificity of gingival overgrowth.  (+info)

Verapamil induced gingival enlargement in cluster headache. (8/47)

Verapamil is an effective prophylactic treatment for cluster headaches and, therefore, is widely used. This report describes four patients with cluster headache who developed gingival enlargement after initiating treatment with verapamil. In two patients, it was possible to control this side effect adequately by optimising oral hygiene and dental plaque control. In the other two patients, lowering of the verapamil dose, in addition to optimal oral hygiene and dental plaque control, was necessary; in one patient verapamil had to be stopped completely to reverse the gingival enlargement. Doctors treating cluster headache with verapamil need to be aware of this side effect, especially as it may be preventable with good dental hygiene and dental plaque control, is reversible with reduction or cessation of verapamil, and can lead to dental loss.  (+info)

Gingival overgrowth, also known as gingival hyperplasia or hypertrophy, refers to an abnormal enlargement or growth of the gum tissue (gingiva) surrounding the teeth. This condition can be caused by various factors, including poor oral hygiene, certain medications (such as phenytoin, cyclosporine, and calcium channel blockers), genetic predisposition, and systemic conditions like vitamin C deficiency or leukemia.

Gingival overgrowth can lead to several complications, such as difficulty in maintaining oral hygiene, which may result in periodontal disease, tooth decay, bad breath, and potential loss of teeth. In some cases, the enlarged gum tissue may also cause discomfort or pain during speaking, chewing, or brushing. Treatment for gingival overgrowth typically involves improving oral hygiene, adjusting medications if possible, and undergoing surgical procedures to remove the excess gum tissue. Regular dental check-ups and cleanings are essential in managing and preventing this condition.

Gingival hyperplasia is a condition characterized by an abnormal growth or enlargement of the gingiva (gum tissue). This condition can be caused by various factors, including bacterial infection, certain medications (such as phenytoin, cyclosporine, and nifedipine), systemic diseases (such as leukemia, vitamin C deficiency, and Crohn's disease), and genetic disorders.

The enlarged gum tissue can be uncomfortable, irritated, and prone to bleeding, especially during brushing or flossing. It may also make it difficult to maintain good oral hygiene, which can increase the risk of dental caries and periodontal disease. Treatment for gingival hyperplasia typically involves improving oral hygiene, controlling any underlying causes, and in some cases, surgical removal of the excess tissue.

Gingiva is the medical term for the soft tissue that surrounds the teeth and forms the margin of the dental groove, also known as the gum. It extends from the mucogingival junction to the base of the cervical third of the tooth root. The gingiva plays a crucial role in protecting and supporting the teeth and maintaining oral health by providing a barrier against microbial invasion and mechanical injury.

Gingival fibromatosis is a benign (non-cancerous) condition characterized by the excessive growth of gum (gingival) tissue. The overgrowth can affect one or both the maxilla (upper jaw) and mandible (lower jaw) and can lead to various dental and oral health issues, such as difficulty in chewing, speaking, and maintaining proper oral hygiene.

The etiology of gingival fibromatosis can be divided into two categories: hereditary and acquired. Hereditary gingival fibromatosis is often associated with genetic mutations, while acquired gingival fibromatosis can result from factors like chronic inflammation due to poor oral hygiene, certain medications (such as phenytoin, cyclosporine, or nifedipine), and systemic conditions (like leukemia).

The management of gingival fibromatosis typically involves surgical removal of the excess tissue. However, recurrence is common due to the condition's tendency for regrowth. Regular follow-ups with a dental professional are essential to monitor any potential regrowth and maintain good oral hygiene.

Gingival diseases are infections or inflammations that affect the gingiva, which is the part of the gum around the base of the teeth. These diseases can be caused by bacteria found in dental plaque and can lead to symptoms such as redness, swelling, bleeding, and receding gums. If left untreated, gingival diseases can progress to periodontal disease, a more serious condition that can result in tooth loss. Common types of gingival diseases include gingivitis and periodontitis.

A gingivectomy is a dental procedure that involves the surgical removal or reshaping of the gum tissue (gingiva) to improve the health and appearance of the teeth and gums. This procedure is typically performed when the gums have become swollen, inflamed, or infected due to periodontal disease, which can cause the gums to recede and expose the tooth roots. By removing the affected gum tissue, a gingivectomy can help to eliminate pockets of bacteria and promote healthy gum growth.

During the procedure, a dental surgeon will use local anesthesia to numb the area and then carefully cut away the excess gum tissue using specialized instruments. The surgeon may also smooth and reshape the remaining gum tissue to create a more even and aesthetically pleasing appearance. After the procedure, patients may experience some discomfort, swelling, or bleeding, but these symptoms can typically be managed with over-the-counter pain medications and careful oral hygiene practices.

It's important to note that while a gingivectomy can help to improve the health of the gums and teeth, it is not a substitute for good oral hygiene habits. Regular brushing, flossing, and dental checkups are essential for maintaining healthy teeth and gums over the long term.

Phenytoin is an anticonvulsant drug, primarily used in the treatment of seizures and prevention of seizure recurrence. It works by reducing the spread of seizure activity in the brain and stabilizing the electrical activity of neurons. Phenytoin is also known to have anti-arrhythmic properties and is occasionally used in the management of certain cardiac arrhythmias.

The drug is available in various forms, including immediate-release tablets, extended-release capsules, and a liquid formulation. Common side effects of phenytoin include dizziness, drowsiness, headache, nausea, vomiting, and unsteady gait. Regular monitoring of blood levels is necessary to ensure that the drug remains within the therapeutic range, as both low and high levels can lead to adverse effects.

It's important to note that phenytoin has several potential drug-drug interactions, particularly with other anticonvulsant medications, certain antibiotics, and oral contraceptives. Therefore, it is crucial to inform healthcare providers about all the medications being taken to minimize the risk of interactions and optimize treatment outcomes.

A gingival pocket, also known as a sulcus, is a small space or groove between the gum tissue (gingiva) and the tooth. It's a normal anatomical structure found in healthy teeth and gums, and it measures about 1-3 millimeters in depth. The purpose of the gingival pocket is to allow for the movement of the gum tissue during functions such as eating, speaking, and swallowing.

However, when the gums become inflamed due to bacterial buildup (plaque) or other factors, the pocket can deepen, leading to the formation of a pathological gingival pocket. Pathological pockets are typically deeper than 3 millimeters and may indicate the presence of periodontal disease. These pockets can harbor harmful bacteria that can cause further damage to the gum tissue and bone supporting the tooth, potentially leading to tooth loss if left untreated.

Gingivitis is a mild form of gum disease (periodontal disease) that causes irritation, redness, swelling and bleeding of the gingiva, or gums. It's important to note that it is reversible with good oral hygiene and professional dental treatment. If left untreated, however, gingivitis can progress to a more severe form of gum disease known as periodontitis, which can result in tissue damage and eventual tooth loss.

Gingivitis is most commonly caused by the buildup of plaque, a sticky film of bacteria that constantly forms on our teeth. When not removed regularly through brushing and flossing, this plaque can harden into tartar, which is more difficult to remove and contributes to gum inflammation. Other factors like hormonal changes, poor nutrition, certain medications, smoking or a weakened immune system may also increase the risk of developing gingivitis.

The dental plaque index (DPI) is a clinical measurement used in dentistry to assess the amount of dental plaque accumulation on a person's teeth. It was first introduced by Silness and Löe in 1964 as a method to standardize the assessment of oral hygiene and the effectiveness of oral hygiene interventions.

The DPI is based on a visual examination of the amount of plaque present on four surfaces of the teeth, including the buccal (cheek-facing) and lingual (tongue-facing) surfaces of both upper and lower first molars and upper and lower incisors. The examiner assigns a score from 0 to 3 for each surface, with higher scores indicating greater plaque accumulation:

* Score 0: No plaque detected, even after probing the area with a dental explorer.
* Score 1: Plaque detected by visual examination and/or probing but is not visible when the area is gently dried with air.
* Score 2: Moderate accumulation of soft deposits that are visible upon visual examination before air drying, but which can be removed by scraping with a dental explorer.
* Score 3: Abundant soft matter, visible upon visual examination before air drying and not easily removable with a dental explorer.

The DPI is calculated as the average score of all surfaces examined, providing an overall measure of plaque accumulation in the mouth. It can be used to monitor changes in oral hygiene over time or to evaluate the effectiveness of different oral hygiene interventions. However, it should be noted that the DPI has limitations and may not accurately reflect the presence of bacterial biofilms or the risk of dental caries and gum disease.

Cyclosporine is a medication that belongs to a class of drugs called immunosuppressants. It is primarily used to prevent the rejection of transplanted organs, such as kidneys, livers, and hearts. Cyclosporine works by suppressing the activity of the immune system, which helps to reduce the risk of the body attacking the transplanted organ.

In addition to its use in organ transplantation, cyclosporine may also be used to treat certain autoimmune diseases, such as rheumatoid arthritis and psoriasis. It does this by suppressing the overactive immune response that contributes to these conditions.

Cyclosporine is available in capsule, oral solution, and injectable forms. Common side effects of the medication include kidney problems, high blood pressure, tremors, headache, and nausea. Long-term use of cyclosporine can also increase the risk of certain types of cancer and infections.

It is important to note that cyclosporine should only be used under the close supervision of a healthcare provider, as it requires regular monitoring of blood levels and kidney function.

A pyogenic granuloma is not precisely a "granuloma" in the strict medical definition, which refers to a specific type of tissue reaction characterized by chronic inflammation and the formation of granulation tissue. Instead, a pyogenic granuloma is a benign vascular tumor that occurs most frequently on the skin or mucous membranes.

Pyogenic granulomas are typically characterized by their rapid growth, bright red to dark red color, and friable texture. They can bleed easily, especially when traumatized. Histologically, they consist of a mass of small blood vessels, surrounded by loose connective tissue and inflammatory cells.

The term "pyogenic" is somewhat misleading because these lesions are not actually associated with pus or infection, although they can become secondarily infected. The name may have originated from the initial mistaken belief that these lesions were caused by a bacterial infection.

Pyogenic granulomas can occur at any age but are most common in children and young adults. They can be caused by minor trauma, hormonal changes, or underlying medical conditions such as pregnancy or vasculitis. Treatment typically involves surgical excision, although other options such as laser surgery or cauterization may also be used.

Nifedipine is an antihypertensive and calcium channel blocker medication. It works by relaxing the muscles of the blood vessels, which helps to lower blood pressure and improve the supply of oxygen and nutrients to the heart. Nifedipine is used to treat high blood pressure (hypertension), angina (chest pain), and certain types of heart rhythm disorders.

In medical terms, nifedipine can be defined as: "A dihydropyridine calcium channel blocker that is used in the treatment of hypertension, angina pectoris, and Raynaud's phenomenon. It works by inhibiting the influx of calcium ions into vascular smooth muscle and cardiac muscle, which results in relaxation of the vascular smooth muscle and decreased workload on the heart."

The Periodontal Index (PI) is not a current or widely used medical/dental term. However, in the past, it was used to describe a method for assessing and measuring the severity of periodontal disease, also known as gum disease.

Developed by Henry H. Klein and colleagues in 1978, the Periodontal Index was a scoring system that evaluated four parameters: gingival inflammation, gingival bleeding, calculus (tartar) presence, and periodontal pocket depths. The scores for each parameter ranged from 0 to 3, with higher scores indicating worse periodontal health. The overall PI score was the sum of the individual parameter scores, ranging from 0 to 12.

However, due to its limited ability to predict future disease progression and the introduction of more comprehensive assessment methods like the Community Periodontal Index (CPI) and the Basic Periodontal Examination (BPE), the use of the Periodontal Index has become less common in dental practice and research.

Orthodontic appliances are devices used in orthodontics, a branch of dentistry focused on the diagnosis, prevention, and treatment of dental and facial irregularities. These appliances can be fixed or removable and are used to align teeth, correct jaw relationships, or modify dental forces. They can include braces, aligners, palatal expanders, space maintainers, and headgear, among others. The specific type of appliance used depends on the individual patient's needs and the treatment plan developed by the orthodontist.

Immunosuppressive agents are medications that decrease the activity of the immune system. They are often used to prevent the rejection of transplanted organs and to treat autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. These drugs work by interfering with the immune system's normal responses, which helps to reduce inflammation and damage to tissues. However, because they suppress the immune system, people who take immunosuppressive agents are at increased risk for infections and other complications. Examples of immunosuppressive agents include corticosteroids, azathioprine, cyclophosphamide, mycophenolate mofetil, tacrolimus, and sirolimus.

HLA-DR2 antigen is a type of human leukocyte antigen (HLA) class II histocompatibility antigen. HLAs are proteins that play an important role in the body's immune system. They help the immune system distinguish between the body's own cells and foreign substances, such as viruses and bacteria.

The HLA-DR2 antigen is found on the surface of certain white blood cells called B lymphocytes and activated T lymphocytes. It is encoded by genes located on chromosome 6 in a region known as the major histocompatibility complex (MHC). The HLA-DR2 antigen is further divided into two subtypes, DRB1*1501 and DRB1*1502.

The HLA-DR2 antigen is associated with an increased risk of developing certain autoimmune diseases, such as multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. It is also associated with an increased susceptibility to certain infectious diseases, such as leprosy and tuberculosis.

It's important to note that having the HLA-DR2 antigen does not guarantee that a person will develop an autoimmune or infectious disease, but it may increase their risk. Other genetic and environmental factors also play a role in the development of these conditions.

Dental care for chronically ill refers to the oral health management and treatment provided to individuals who have chronic medical conditions. These patients often require specialized dental care due to their increased risk of developing oral health problems as a result of their underlying medical condition or its treatment. The goal of dental care for the chronically ill is to prevent and manage dental diseases, such as tooth decay and gum disease, in order to maintain overall health and quality of life. This may involve close collaboration between dental professionals, physicians, and other healthcare providers to ensure that the patient's oral health needs are being met in a comprehensive and coordinated manner.

Gingival crevicular fluid (GCF) is defined as the serum transudate or inflammatory exudate that flows from the gingival sulcus or periodontal pocket. It is a physiological fluid found in the narrow space between the tooth and the surrounding gum tissue, which deepens during periodontal disease. The analysis of GCF has been used as a non-invasive method to assess the status of periodontal health and disease since it contains various markers of inflammation, host response, and bacterial products.

Calcium channel blockers (CCBs) are a class of medications that work by inhibiting the influx of calcium ions into cardiac and smooth muscle cells. This action leads to relaxation of the muscles, particularly in the blood vessels, resulting in decreased peripheral resistance and reduced blood pressure. Calcium channel blockers also have anti-arrhythmic effects and are used in the management of various cardiovascular conditions such as hypertension, angina, and certain types of arrhythmias.

Calcium channel blockers can be further classified into two main categories based on their chemical structure: dihydropyridines (e.g., nifedipine, amlodipine) and non-dihydropyridines (e.g., verapamil, diltiazem). Dihydropyridines are more selective for vascular smooth muscle and have a greater effect on blood pressure than heart rate or conduction. Non-dihydropyridines have a more significant impact on cardiac conduction and contractility, in addition to their vasodilatory effects.

It is important to note that calcium channel blockers may interact with other medications and should be used under the guidance of a healthcare professional. Potential side effects include dizziness, headache, constipation, and peripheral edema.

Connective Tissue Growth Factor (CTGF) is a cysteine-rich peptide growth factor that belongs to the CCN family of proteins. It plays an important role in various biological processes, including cell adhesion, migration, proliferation, and extracellular matrix production. CTGF is involved in wound healing, tissue repair, and fibrosis, as well as in the pathogenesis of several diseases such as cancer, diabetic nephropathy, and systemic sclerosis. It is expressed in response to various stimuli, including growth factors, cytokines, and mechanical stress. CTGF interacts with a variety of signaling molecules and integrins to regulate cellular responses and tissue homeostasis.

Anticonvulsants are a class of drugs used primarily to treat seizure disorders, also known as epilepsy. These medications work by reducing the abnormal electrical activity in the brain that leads to seizures. In addition to their use in treating epilepsy, anticonvulsants are sometimes also prescribed for other conditions, such as neuropathic pain, bipolar disorder, and migraine headaches.

Anticonvulsants can work in different ways to reduce seizure activity. Some medications, such as phenytoin and carbamazepine, work by blocking sodium channels in the brain, which helps to stabilize nerve cell membranes and prevent excessive electrical activity. Other medications, such as valproic acid and gabapentin, increase the levels of a neurotransmitter called gamma-aminobutyric acid (GABA) in the brain, which has a calming effect on nerve cells and helps to reduce seizure activity.

While anticonvulsants are generally effective at reducing seizure frequency and severity, they can also have side effects, such as dizziness, drowsiness, and gastrointestinal symptoms. In some cases, these side effects may be managed by adjusting the dosage or switching to a different medication. It is important for individuals taking anticonvulsants to work closely with their healthcare provider to monitor their response to the medication and make any necessary adjustments.

Gingival neoplasms refer to abnormal growths or tumors that occur in the gingiva, which are the part of the gums that surround the teeth. These growths can be benign (non-cancerous) or malignant (cancerous). Benign neoplasms include conditions such as fibromas, papillomas, and hemangiomas, while malignant neoplasms are typically squamous cell carcinomas.

Gingival neoplasms can present with a variety of symptoms, including swelling, bleeding, pain, and loose teeth. They may also cause difficulty with chewing, speaking, or swallowing. The exact cause of these neoplasms is not always known, but risk factors include tobacco use, alcohol consumption, poor oral hygiene, and certain viral infections.

Diagnosis of gingival neoplasms typically involves a thorough clinical examination, including a dental exam and biopsy. Treatment options depend on the type and stage of the neoplasm, but may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular dental check-ups and good oral hygiene practices can help to detect gingival neoplasms at an early stage and improve treatment outcomes.

Connective tissue is a type of biological tissue that provides support, strength, and protection to various structures in the body. It is composed of cells called fibroblasts, which produce extracellular matrix components such as collagen, elastin, and proteoglycans. These components give connective tissue its unique properties, including tensile strength, elasticity, and resistance to compression.

There are several types of connective tissue in the body, each with its own specific functions and characteristics. Some examples include:

1. Loose or Areolar Connective Tissue: This type of connective tissue is found throughout the body and provides cushioning and support to organs and other structures. It contains a large amount of ground substance, which allows for the movement and gliding of adjacent tissues.
2. Dense Connective Tissue: This type of connective tissue has a higher concentration of collagen fibers than loose connective tissue, making it stronger and less flexible. Dense connective tissue can be further divided into two categories: regular (or parallel) and irregular. Regular dense connective tissue, such as tendons and ligaments, has collagen fibers that run parallel to each other, providing great tensile strength. Irregular dense connective tissue, such as the dermis of the skin, has collagen fibers arranged in a more haphazard pattern, providing support and flexibility.
3. Adipose Tissue: This type of connective tissue is primarily composed of fat cells called adipocytes. Adipose tissue serves as an energy storage reservoir and provides insulation and cushioning to the body.
4. Cartilage: A firm, flexible type of connective tissue that contains chondrocytes within a matrix of collagen and proteoglycans. Cartilage is found in various parts of the body, including the joints, nose, ears, and trachea.
5. Bone: A specialized form of connective tissue that consists of an organic matrix (mainly collagen) and an inorganic mineral component (hydroxyapatite). Bone provides structural support to the body and serves as a reservoir for calcium and phosphate ions.
6. Blood: Although not traditionally considered connective tissue, blood does contain elements of connective tissue, such as plasma proteins and leukocytes (white blood cells). Blood transports nutrients, oxygen, hormones, and waste products throughout the body.

Kidney transplantation is a surgical procedure where a healthy kidney from a deceased or living donor is implanted into a patient with end-stage renal disease (ESRD) or permanent kidney failure. The new kidney takes over the functions of filtering waste and excess fluids from the blood, producing urine, and maintaining the body's electrolyte balance.

The transplanted kidney is typically placed in the lower abdomen, with its blood vessels connected to the recipient's iliac artery and vein. The ureter of the new kidney is then attached to the recipient's bladder to ensure proper urine flow. Following the surgery, the patient will require lifelong immunosuppressive therapy to prevent rejection of the transplanted organ by their immune system.

GUSMAO, Estela Santos et al. Gingival overgrowth associated the climateric: surgical removal. Rev. cir. traumatol. buco-maxilo- ... A case report of a localized gingival overgrowth in the palate region in a 49-year-old female patient in the climacteric period ...
Gum Swelling (Gingival Overgrowth). Some medications can cause a buildup of gum tissue, a condition called "gingival overgrowth ... Gingival overgrowth increases your risk of periodontal disease. Swollen gum tissue creates a favorable environment for bacteria ...
... André Guollo, Ana Paula Molina Vivas, Rodrigo ... Incidence of amlodipineinduced gingival overgrowth in the rural population of Loni. J Indian Soc Periodontol. 2014;18(2):226-8 ... Drug-induced gingival overgrowth (GO) has been associated with phenytoin, cyclosporine, and calcium channel blocker therapies. ... Gingival overgrowth in renal transplant subjects medicated with tacrolimus in the absence of calcium channel blockers. ...
α2 integrin +807 polymorphism in drug-induced gingival overgrowth. / Ogino, M.; Kido, J.; Bando, M. et al. In: Journal of ... α2 integrin +807 polymorphism in drug-induced gingival overgrowth. M. Ogino, J. Kido, M. Bando, N. Hayashi, C. Wada, T. Nagata ... α2 integrin +807 polymorphism in drug-induced gingival overgrowth. In: Journal of Dental Research. 2005 ; Vol. 84, No. 12. pp. ... α2 integrin on fibroblasts is reported to play an important role in the induction of drug-induced gingival overgrowth, which is ...
443/pdfviewer/article-treatment-of-amlodipine-induced-gingival-overgrowth-article/ Thank You ...
... "drug induced gingival enlargement" or "drug influenced gingival overgrowth", abbreviated to "DIGO". Gingival enlargement may ... Gingival overgrowth is a common side effect of phenytoin, termed "Phenytoin-induced gingival overgrowth" (PIGO). ... Gingival enlargement is an increase in the size of the gingiva (gums). It is a common feature of gingival disease. Gingival ... Subramani, T; Rathnavelu, V; Yeap, SK; Alitheen, NB (Feb 2013). "Influence of mast cells in drug-induced gingival overgrowth". ...
FONSECA, Luciara Viana Leão et al. Epidemiological analysis of nifedipine and phenytoin-induced gingival overgrowth in users of ... Keywords : Nifedipine; phenytoin; gingival overgrowth; primary health care. · abstract in Portuguese · text in English · pdf in ... PURPOSES: The aim of this study was to evaluate the prevalence of drug-induced gingival overgrowth (DIGO) in Brazilian users of ... Clinical evaluations including gingival overgrowth analysis were carried out by a single calibrated examiner. Bivariate ...
... with the result of an overgrowth. Nevertheless, the overgrowth involves the gingival margin with extension to the inter-dental ... Aim of this study is to describe an operative protocol for the surgical treatment of localized gingival overgrowth analyzing ... Severe overgrowth may lead to impairment in aesthetic and masticatory functions, requiring surgical excision of the excessive ... From: Surgical treatment of gingival overgrowth with 10 years of follow-up ...
The polymorphism in the TGF-beta1 gene at codon 25 represented an independent genetic determinant of severe gingival overgrowth ... The purpose of this study was to determine whether the prevalence and severity of gingival overgrowth in renal transplant ... Polymorphisms in the TGF-beta1 gene influence the expression of gingival overgrowth in renal transplant recipients ... The extent and severity of gingival overgrowth for 164 renal transplant recipients immunosuppressed with cyclosporin A and ...
drug-induced gingival overgrowth. drug-induced gingival enlargement. drug-induced gingival hyperplasia. drug-induced gingival ... Gingival overgrowth or enlargement is an esthetically disfiguring condition characterized by increased gingival connective ... Thompson A. L., Herman W. W., Konzelman J, Collins M. A., . Treating patients with drug-induced gingival overgrowth. J Dent Hyg ... Arya R, Gulati S, . Phenytoin-induced gingival overgrowth. Acta Neurol Scand. 2012;125(3):149-155. [Google Scholar] ...
Gingival overgrowth in a child with arthrogryposis treated with a Er,Cr:YSGG laser: A case report. ... Dive into the research topics of Gingival overgrowth in a child with arthrogryposis treated with a Er,Cr:YSGG laser: A case ...
... if considering the quite numerous studies devoted to the clinical aspects and treatment of such pathological gingival ... Home 2017 Vol 21 Issue 1 CLINICAL AND THERAPEUTICAL ASPECTS OF GINGIVAL OVERGROWTHS INDUCED BY ANTICONVULSIVE DRUGS (PHENYTOIN) ... CLINICAL AND THERAPEUTICAL ASPECTS OF GINGIVAL OVERGROWTHS INDUCED BY ANTICONVULSIVE DRUGS (PHENYTOIN). ... For example, gingival hyperplasia induced by phenytoin is more frequent in children and adolescents than in adult persons. An ...
KEYWORDS: Nifedipine; Gingival Overgrowth; Gingival Fibroblast; TRPV1 Channel JOURNAL NAME: Pharmacology & Pharmacy, Vol.3 No.4 ... ABSTRACT: Background: Among anti-hypertension drugs, calcium (Ca2+) antagonists cause gingival overgrowth as a side effect. We ... Methods Normal human gingival fibroblast Gin-1 cells were used. The [Ca2+]i was measured using a video-imaging analysis system ... In the present study, we undertook experiments to determine if TRPV1 channels are present in gingival fibroblasts and to ...
Some affected individuals have overgrowth of the gums (gingival hyperplasia. ), an opening in the roof of the mouth (cleft ...
Drug-induced gingival overgrowth and its management. Seymour RA, Ellis JS, Thomason JM. Seymour RA, et al. Among authors: ellis ... Amlodipine-induced gingival overgrowth. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Seymour RA, et al. Among authors ... Risk factors for drug-induced gingival overgrowth. Seymour RA, Ellis JS, Thomason JM. Seymour RA, et al. Among authors: ellis ... The pathogenesis of drug-induced gingival overgrowth. Seymour RA, Thomason JM, Ellis JS. Seymour RA, et al. Among authors: ...
... and the most recognized is drug-induced gingival enlargement. Furthermore, causes of congenital gingival enlargement include ... No age predilection exists for the onset of drug-induced gingival overgrowth; however, phenytoin-induced gingival overgrowth ... Drug-induced gingival overgrowth, also known as gingival hyperplasia secondary to drugs, was first reported in the dental ... Morbidity can be severe in some cases because of gross overgrowth of gingival tissue, which can lead to gingival bleeding, pain ...
Categories: Gingival Overgrowth Image Types: Photo, Illustrations, Video, Color, Black&White, PublicDomain, CopyrightRestricted ...
The use of a common medication for high blood pressure led to gingival overgrowth in a man with poor oral health. Details of ... Hypertension medication causes mans rare gingival overgrowth. ...
12/01/1997 - "Gingival overgrowth and dental alveolar alterations: possible mechanisms of cyclosporin-induced tooth migration. ...
Medical Management of Cyclosporine-Induced Gingival Overgrowth Using Oral Azithromycin in Six Dogs ...
Gingival overgrowth is an adverse outcome of cyclosporine A (CsA) treatment, involving disruption of collagen remodeling. ... Role of discoidin domain receptor 1 in cyclosporine A-induced gingival overgrowth Par Stephen Spano, Université de Toronto ... Accordingly, CsA perturbation of DDR1-mediated fibrillar reorganization may contribute to gingival overgrowth. ...
... alone do not led to clear phenotypes with gingival fibromatosis, whereas the double mutations led to gingival hyperplasia ... ZNF513 combined with KIF3C regulates gingival fibroblast proliferation, migration, and fibrosis response via the PI3K/AKT/mTOR ... binds to KIF3C exon 1 and participates in the positive regulation of KIF3C expression in gingival fibroblasts. Furthermore, a ... is a rare inherited condition with fibromatoid hyperplasia of the gingival tissue that exhibits great genetic heterogeneity. ...
Epithelial-Mesenchymal Transition - A Possible Pathogenic Pathway of Fibrotic Gingival Overgrowth By Ileana Monica Baniţă, ...
Phenytoin-sodium induced gingival overgrowth  Radomsky, Jack Bernard (University of Stellenbosch, 1984) ... Shortly after its introduction, the side-effect of gingival overgrowth was re{XJrted ... ...
... and the most recognized is drug-induced gingival enlargement. Furthermore, causes of congenital gingival enlargement include ... No age predilection exists for the onset of drug-induced gingival overgrowth; however, phenytoin-induced gingival overgrowth ... Drug-induced gingival overgrowth, also known as gingival hyperplasia secondary to drugs, was first reported in the dental ... Morbidity can be severe in some cases because of gross overgrowth of gingival tissue, which can lead to gingival bleeding, pain ...
... also known as gingival hyperplasia or hypertrophy. Gingival enlargement is the abnormal overgrowth of gingival tissues. The ... Gingival Enlargement. Your swollen gums might actually be gingival enlargement, ...
When the drug was withdrawn ,there was a marked regression of the gingival hyperplasia. Nevertheless, the spasms persisted (N ... overgrowth of gum tissue). The boy also suffered from cerebellar spasms, which caused a loss of control of some facial features ... Examination of the boy after this time revealed coarsening of facial features as well as severe gingival hyperplasia ( ... Tagged asanticonvulsantsgingival hyperplasiagum damagephenytoinWhat Doctors Dont Tell You ...
Gingival overgrowth. *Malignancy of WBCs. *Gingival bleeding & oral petechiae. *Oral ulcers. *Downs Syndrome. *Trisomy 21. ...
There is an increase in periodontal probing depths due to the gingival overgrowth. ... Supra-gingival calculus per se does not exert an irritant effect on the gingival tissues. The main importance of calculus in ... Gingival hyperplasia does pose an additional concern. The hyperplastic gingiva alters the position of the gingival margin and ... Gingival hyperplasia may be the result of plaque-induced inflammation, i.e., hyperplastic gingivitis. It may also be of ...

No FAQ available that match "gingival overgrowth"

No images available that match "gingival overgrowth"